Viriom

Viriom Inc. is a biotechnology company based in Khimki, Russia, that specializes in developing affordable medicines for life-threatening infections, particularly HIV/AIDS and Hepatitis B virus (HBV). Founded in 2009, Viriom holds exclusive worldwide licenses for its lead compounds, Elpida/elsulfavirine and VM1500A, which are in phase 3 and commercial stages, respectively. The company has also created proprietary drug candidates, including VM2500 and VM3500, along with long-acting injectable formulations and combinations with cell, vaccine, and antibody drugs, aimed at treating, preventing, and potentially curing HIV and chronic HBV infections. Viriom's innovative approach seeks to enhance treatment options for patients worldwide.